Tests dendritic cell vaccines in multiple myeloma patients in remission
Tests whether engineered dendritic cell vaccines are feasible and safe in multiple myeloma.
Plain-language title generated from the registry record
Registry title: Engineered Dendritic Cell Vaccines for Multiple Myeloma
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06435910, who can take part
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT06435910
- Record updated
- 2 November 2026
- Original description
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.Read full original descriptionShow less
Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Inclusion: Male and female subjects with multiple myeloma or plasmacytoma; Very good partial or complete remission (CR) after prior combination therapies; Expected survival > 12 weeks; Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal; Voluntary informed consent is given with willingness to continue follow up.
Exclusion: Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary; Uncontrolled active infection; HIV or active hepatitis B or hepatitis C infection; Pregnant or lactating women.